CCL5 and brain infarction: Treatment with RANTES antagonists reduced tissue damage in IRI-related diseases such as myocardial infarction or brain infarction by significant decrease in infiltrating inflammatory cells, such as neutrophils, macrophages and lymphocytes7, 10.